Small size, big impact

By SPI Pharma

Small molecule drugs have stood the test of time as the preeminent pharmaceutical method for treating patients. What this also means is that competition in the space is fierce, and every advantage matters – both in terms of manufacturing costs and product performance. Bill McCarthy, director of marketing at SPI Pharma, explains how the company’s S-Tab tablet platform offers both of these advantages, as well as enabling companies to bring products to market and scale them faster.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.